As a well-established therapeutic target, HER2-directed therapies, such as trastuzumab, pertuzumab, and other anti-HER2 agents, have dramatically improved breast cancer-specific outcomes in HER2-positive breast cancers. The gene discussed is ERBB2; the disease is breast carcinoma.